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take one-half tablet. Staff was notiﬁed of the program-
ming change prior to execution, to ensure proper coun-
selling of patients. It was assumed that the rate of tablet
splitting would have remained unchanged without the
electronic implementation. Therefore, cost savings for
each medication and dose was calculated by multiplying
the absolute number of prescriptions by the percent
increase in tablet splitting realized. Difference in cost per
year between utilizing whole and half tablets was applied
to the additional number of prescriptions tablet split.
RESULTS: Analysis was performed on selected prescrip-
tion data including rosiglitazone, atorvastatin, simvas-
tatin, sertraline, paroxetine, risperidone, and olanzapine.
Prior to implementation, only 65% (3918/6000) of eligi-
ble prescriptions were tablet split. Within 6 months, the
rate increased to 80% (5357/6680) with an estimated
annual cost savings of US$158,000.00. Rate increased
10–92% per medication. CONCLUSIONS: Incorporat-
ing a tablet splitting guide with physician order entry is
an efﬁcient method of realizing substantial cost savings.
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OBJECTIVES: Quantifying the impact of falling on
health care utilization and costs is important for under-
standing the economic consequences of this problem, and
for gauging the potential beneﬁts from falls prevention
programs. METHODS: The study examines a unique
falls database of older, community-dwelling individuals.
We examine costs for emergency room care, hospitaliza-
tion. Home health care, and long-term care. We also
investigate total costs, using both two-part models and
propensity scoring methods. The two-part model is a tra-
ditional approach to estimating costs when costs depend
on the decision to use care as well as on costs conditional
on use. The propensity scoring approach provides a non-
parametric alternative. RESULTS: Relative to nonfallers,
individuals incurring a single fall have total annual costs
that are $4484 to $8177 higher. The larger estimate 
was obtained using propensity scoring techniques. For
multiple fallers, total costs increase from $7,422 (2-part
method) to $13,045 (propensity scoring method). These
differences are highly signiﬁcant (p < 0.01). Falling 
signiﬁcantly increases each type of health care cost 
examined, and the estimated effects are greater using the
propensity score approach. For single fallers, emergency
room costs increase by $106 to $119 annually; hospital
costs by $2787 to $4856; home health care costs by 
$153 to $291; and long term care costs by $1,710 
to $2913. For multiple fallers, emergency room costs
increase by $123 to $158; hospital costs by $3916 to
$4510; home health care costs by $371 to $755; and long
term care costs by $2541 to $7621. These patterns pri-
marily reﬂect a greater tendency to utilize care rather than
a greater intensity of treatment among users of care.
CONCLUSIONS: Falling raises health care costs sub-
stantially. The results using propensity scoring methods
suggest that the magnitude of these effects may be sub-
stantially greater than suggested by previous research that
used traditional parametric approaches.
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OBJECTIVES: In this study, a decision model analysis
was performed, comparing the overall clinical efﬁcacy
and total costs in the treatment of tibial nonunions in the
UK and in Germany. In the UK treatment with osteogenic
protein 1 (OP-1) was compared to autograft or the
Ilizarov ﬁxation technique, and in Germany treatment
with OP-1 was compared to ﬁxation with a nail or a plate
and if appropriate autograft. METHODS: The analysis
was based on a decision tree. Data on efﬁcacy were
obtained from clinical trials and literature. Medical
resource use data were obtained from country-speciﬁc
expert panels. UK and German hospital direct medical
costs of treatment were determined using standard
costing techniques. The primary end-point was the total
average cost of treatment of tibial nonunions. Univariate
sensitivity analyses were performed to test the robustness
of the model. RESULTS: In the UK, total cost per average
patient receiving OP-1 treatment were £8797 compared
to £9084 for autograft and £9722 for the Ilizarov ﬁxa-
tion technique. The cost effectiveness ratio, cost per
patient with a healed fracture, was comparable between
the 3 treatment options; £10,860 for OP-1 treatment,
£10,687 for autograft treatment and £10,234 for the
Ilizarov ﬁxation technique. In Germany, total cost per
average patient receiving OP-1 treatment were €15,156
compared to €14,348 for usual care. The cost effective-
ness ratio, cost per patient with a healed fracture, was
better for usual care than for OP-1, but only slightly so.
CONCLUSIONS: This study indicates that OP-1 is a
good alternative treatment for tibial nonunions, both
from a clinical and an economic perspective. Parameters
inﬂuencing cost-effectiveness included % of adverse
events and number of days in hospital. Prospective data
is needed to conﬁrm these results.
